title: New paradigm for treating recurrent depression: from symptom control to managing enduring vulnerabilities.
abstract: Optimal management of depression remains a long-term challenge. Long-term maintenance treatment with antidepressants has been shown to be effective for preventing or delaying recurrence for many patients with a history of previous multiple episodes. However, aside from a history of multiple recurrences, it remains difficult to identify patients who are most likely to experience recurrence and when. Thus we do not really know who might particularly benefit from maintenance therapy and what type may be efficacious. In patients with depression, research has shown there are structural and functional alterations in the brain, particularly in patients with recurrent or chronic depression. These changes have been generally viewed to be consequences of the disease, which are seen to worsen with a longer duration of untreated illness and with a greater number of depressive episodes. However, these neurobiological characteristics may also represent risk factors or vulnerabilities that predispose some patients to chronic or recurrent depression. Additional research has demonstrated that antidepressant treatment may reduce or modulate these functional and structural changes, suggesting that long-term treatment may, in fact, benefit patients not only by controlling symptoms but also by managing these underlying vulnerabilities. A new treatment paradigm, which focuses on identifying patients with risk factors and managing the disease process rather than suppression of symptoms, is needed for recurrent depression.
authors.affiliation: Stanford University School of Medicine, CA 94605-5548, USA. afschatz@leland.stanford.edu
authors.forename: Alan F
authors.initials: AF
authors.lastname: Schatzberg
mesh_terms: D003865:Major Depressive Disorder / Q000235:genetics / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D007030:Hypothalamo-Hypophyseal System / Q000503:physiopathology; D010913:Pituitary-Adrenal System / Q000503:physiopathology; D012008:Recurrence; D050486:Serotonin Plasma Membrane Transport Proteins / Q000235:genetics
chemical_list: D050486:Serotonin Plasma Membrane Transport Proteins